Rare pulmonary disease specialist aims to raise $650 million

Serious and rare disease company Insmed (Nasdaq: INSM) has launched a public offering with the goal of raising $650 million.

The New Jersey, USA-based biotech plans to use the net proceeds from this offering in part to fund the continued research and development of brensocatib.

Brensocatib, Insmed’s promising drug candidate for non-cystic fibrosis bronchiectasis (NCFBE), shows potential to become a significant revenue driver.